Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.48 |
| ▸ | ROCK2 known ✓ | O75116 | 2/20 | 0.41 |
| ▸ | ROCK1 known ✓ | Q13464 | 2/20 | 0.41 |
| ▸ | CASR known ✓ | P41180 | 2/20 | 0.40 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.64 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20266800 | 1.00 | PDE2A (0.64) | PDE2AADRB2NOS1KIF11CES2 | |
| Hydrochloric Acid SCHEMBL27940422 | 1.00 | PDE2A (0.64) | PDE2AADRB2NOS1KIF11CES2 | |
| SCHEMBL268077 | 0.98 | PDE2A (0.67) | PDE2AADRB2NOS1KIF11CES2 | |
| SCHEMBL701658 | 0.98 | PDE2A (0.67) | PDE2AADRB2NOS1KIF11CES2 | |
| SCHEMBL335039 | 0.98 | PDE2A (0.67) | PDE2AADRB2NOS1KIF11CES2 | |
| Iodide SCHEMBL28800992 | 0.95 | PDE2A (0.64) | PDE2AADRB2NOS1KIF11CES2 | |
| Bromide SCHEMBL28801001 | 0.95 | PDE2A (0.64) | PDE2AADRB2NOS1KIF11CES2 | |
| SCHEMBL30913861 | 0.91 | PDE2A (0.60) | PDE2AADRB2KIF11CASR | |
| Hydrochloric Acid SCHEMBL30542084 | 0.86 | PDE2A (0.50) | PDE2AADRB2NOS1KIF11CES2 | |
| SCHEMBL13448214 | 0.86 | PDE2A (0.55) | PDE2AADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648762-A2 | PPARG MODULATORS | University of Florida Research Foundation, Incorporated (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12465588-B2 | Indole carboxamide derivative and pharmaceutical composition containing same | KUKJE PHARMA CO., LTD. (KR) | 2025-11-11 | — | — | US | disclosed |
| US-20250163065-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2025-05-22 | — | — | US | disclosed |
| US-20240245691-A1 | 2-METHYLENE-4-OXO-BUTANOIC ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | SITRYX THERAPEUTICS LIMITED (GB) | 2024-07-25 | — | — | US | disclosed |
| US-RE50050-E1 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024151519-A2 | PPARG MODULATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATIN, INCORPORATED (US) | 2024-07-18 | — | — | WO | disclosed |
| EP-4330231-A1 | 2-METHYLENE-4-OXO-BUTANOIC ACID DRIVATIVES FOR THE TREATMENT OF INFLAMMATION | Sitryx Therapeutics Limited (GB) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023165263-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海科技大学 | 2023-09-07 | — | — | WO | disclosed |
| WO-2023165262-A1 | THIENO-NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海科技大学 | 2023-09-07 | — | — | WO | disclosed |
| CN-116693536-A | Pyrrolotriazinone compound, pharmaceutical composition containing pyrrolotriazinone compound, preparation method and application of pyrrolotriazinone compound | 上海科技大学 | 2023-09-05 | — | — | CN | disclosed |
| WO-2021040393-A1 | INDOLE CARBOXAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 국제약품 주식회사 | 2021-03-04 | — | — | WO | disclosed |
| US-10357481-B2 | Substituted triazolo bicyclic compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME LLC | 2018-06-21 | — | — | US | disclosed |
| CN-103635472-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2018-01-12 | — | — | CN | disclosed |
| US-9181200-B2 | Pyrimidinedione compounds | MyoKardia, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | MyoKardia, Inc. | 2014-12-25 | — | — | US | disclosed |
| CN-103635472-A | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC | 2014-03-12 | — | — | CN | disclosed |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | GLAXO GROUP LIMITED | 2008-06-05 | — | — | US | disclosed |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-3996232-A | ANTIULCER AGENTS | WILLIAM H. RORER, INC. (US) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465588-B2 | Indole carboxamide derivative and pharmaceutical composition containing same | PTGES, PTGES2, PTGS1 | ADRB2 702/4885ROCK2 1665/4885ROCK1 1580/4885 |
| US-20140378464-A1 | PYRIMIDINEDIONE COMPOUNDS | TYMS, TYMP, DPYD | ADRB2 1818/4885ROCK2 4328/4885ROCK1 4172/4885 |
| US-20180169072-A1 | SUBSTITUTED TRIAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS | PDE2A, PDE3A, PDE4D | ADRB2 171/4885ROCK2 77/4885ROCK1 427/4885 |
| US-20080132536-A1 | PYRAZOLO [3,4-B] PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | ADRB2 429/4885ROCK2 330/4885ROCK1 141/4885 |
| US-20070111995-A1 | Pyrazolo [3,4-B] pyridine Compounds and Their Use as Phosphodiesterase Inhibitors | PDE4B, PDE3B, PDE4A | ADRB2 52/4885ROCK2 397/4885ROCK1 195/4885 |
| US-10357481-B2 | Substituted triazolo bicyclic compounds as PDE2 inhibitors | PDE2A, PDE3A, PDE4D | ADRB2 171/4885ROCK2 77/4885ROCK1 427/4885 |
| US-20240245691-A1 | 2-METHYLENE-4-OXO-BUTANOIC ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | HCAR2, NFKBIA, TNF | ADRB2 502/4885ROCK2 1114/4885ROCK1 1514/4885 |
| US-20250163065-A1 | PYRROLOTRIAZINONE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | GPR139, GPR132, GPR142 | ADRB2 112/4885ROCK2 3471/4885ROCK1 2795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.